MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/hae.14347

Медицинская библиотека · Haemophilia : the official journal of the World Federation of Hemophilia · 2021

Real-world cost estimates of initiating emicizumab in US patients with haemophilia A.

Samelson-Jones Benjamin J, Guelcher Christine, Kuhn Jan, Butler Regina, Massey Gita, Guerrera Michael F, Raffini Leslie

СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПеревод в очереди

Аннотация

INTRODUCTION

Emicizumab is the first approved non-factor therapy for haemophilia A. It provides superior prophylactic bleeding control compared to other products in both patients with and patients without inhibitors. However, there is no real-world data about the monetary consequences of starting emicizumab.

AIM: To examine the estimated costs of starting emicizumab in a cohort of real-world haemophilia A patients with and without inhibitors.

METHODS

The cost of haemostatic therapy for 6 months before and after initiating emicizumab for participants in a multicentre observational study was calculated based on the type of product and dosing that was used for prophylaxis and treating breakthrough bleeds, the number of treated bleeds and the participant weight.

RESULTS

Ninety-two patients were included, 18 with an active inhibitor. The median age was 8.7 years. The median total cost for all patients decreased from $176,720 to $128,099 (p = .04) after initiating emicizumab, largely because of decrease in the total cost of high-cost outliers. The cost of prophylaxis and the total cost of bleeds also significantly decreased after starting emicizumab, both for patient with and patients without inhibitors.

CONCLUSIONS

Starting or switching to prophylaxis with emicizumab results in decreased costs for the treatment of patients with haemophilia A. This real-world data could inform on payer decisions as well as future cost-effective analysis.

Для цитирования: Samelson-Jones Benjamin J, Guelcher Christine, Kuhn Jan, Butler Regina, Massey Gita, Guerrera Michael F, Raffini Leslie. Real-world cost estimates of initiating emicizumab in US patients with haemophilia A.. Haemophilia : the official journal of the World Federation of Hemophilia. 2021. DOI: 10.1111/hae.14347.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.